Saturday, 3 October 2026

The week in review

The close-of-day market read on Friday stayed risk-off, unchanged from the prior read, because too few stocks are in uptrends, even though the index itself is not falling.

Breadth sets the call. The regime rules turn risk-off whenever breadth is under 40%, so the call holds regardless of the index level.

The index tells a calmer story. SPY, the exchange-traded fund that tracks the S&P 500, closed at 769.65. Its 200-day EMA is 724.37, which puts SPY +6.3% above that line. The VIX volatility index stands at 15.31, a calm reading. A rising index alongside a shrinking share of rising stocks suggests a market carried by a narrow group of large names.

Credit moved more than equity volatility did. The high-yield credit spread, the extra yield investors demand to hold junk bonds, stood at 3.24% on 1 October 2026, up 31 basis points week over week, according to Federal Reserve data. Lenders asked for more compensation even as the VIX stayed calm.

Long-term rates rose and short-term rates eased. The 10-year Treasury yield was 5.24% on 1 October 2026, up 7 basis points week over week. The 2-year yield was 4.78%, down 3 basis points. The 10-year minus 2-year spread was 0.45% on 2 October 2026, up 9 basis points. The real 10-year rate, which is the yield after expected inflation, was 2.88%, up 5 basis points. The labor data show no strain: initial jobless claims were 197K for the week of 26 September 2026.

The risk-off read is a view about the market's internal condition. Breadth alone holds it there. A move back to 40% or above ends the risk-off call; from there the call reads neutral until breadth reaches 55% with SPY still at least 5% above its 200-day EMA (above 60% otherwise) and the VIX below 28. Rates, credit and labor data give context but do not move the call.

Themes in motion

The health-care narratives are the ones gaining strength, while the AI hardware stories are maturing and the AI software stories are saturated.

The medtech and diagnostics theme is accelerating. The precision biotech and therapeutics theme is accelerating as well. Both are moving against a weak-breadth market. This suggests the strength comes from company-specific news more than from a broad rally.

Several AI hardware stories are maturing. These are AI datacenter infrastructure, AI chips and memory, semiconductor foundry and equipment, and analog semiconductors. The consumer discretionary rotation theme is also maturing.

Three narratives are saturated: AI enterprise software, Cybersecurity, and GPU cloud and neoclouds. A saturated theme is widely known, which leaves less room for new information to move it.

The view that health care leads would be wrong if either accelerating theme slipped back to maturing while the regime stayed risk-off.

Under the lens

The research rates Sandisk as its highest-conviction name this week, on the case that its contracted recovery in AI storage is now confirmed by its supplier and peer data. The research team refreshed 1,020 dossiers this week.

• Sandisk Corporation (SNDK). Sandisk sells contracted storage to AI customers. The published thesis holds that this recovery is now supported by two things: Micron's earnings beat on 30 September 2026 and a rise in NAND memory prices. The name sits within the maturing AI chips and memory theme. Sandisk's own next quarterly report settles the case. The thesis is confirmed if that report shows the contracted AI-storage revenue arriving. It breaks if NAND pricing reverses or the report shows no recovery.

One name is too few to support a conclusion about the memory theme as a whole.

The week ahead

The coming week's dated events are mostly conferences and procedural deadlines; the OPEC+ meeting on Sunday is the one that could reset a price.

• OPEC+ meeting, Sunday, 4 October. The meeting sets November output targets. It bears on Baytex Energy (BTE), Kosmos Energy (KOS) and the United States Oil Fund (USO). A higher output target would test the supply case for these three. An unchanged target would leave it intact.
• Diagnostics and cell-therapy meetings, 3 October to 7 October. Caris Life Sciences (CAI) is attending CAP 2026, the College of American Pathologists meeting, through 6 October. Cytek Biosciences (CTKB) holds a corporate workshop on 4 October at the ICCS 2026 meeting in Miami. CryoPort (CYRX) appears at the Cell & Gene Meeting on the Mesa in Phoenix from 5 October to 7 October. Fresh commercial updates at these meetings would add evidence for the accelerating medtech and diagnostics theme. Repeated messaging would add nothing.
• Kymera Therapeutics (KYMR), 3 October. The EADV congress, the European dermatology and venereology meeting, closes. Kymera's presentations cover KT-621 Phase 1b data that has already been reported, so the event confirms the existing record and is unlikely to change it.
• Xos (XOS), 4 October to 7 October. The APTA TRANSform Conference & EXPO, a public-transit industry show, runs in Chicago. It gives Xos a venue for transit-fleet announcements.
• COMPASS Pathways (CMPS), 5 October. Written comments are due for the FDA psychedelics hearing, docket FDA-2026-N-7542. The comment record shapes how the agency frames the field ahead of the hearing.
• Alibaba (BABA), 5 October. The lead-plaintiff deadline falls in securities class action 1:26-cv-06654. It is a procedural step that settles who leads the case, not the merits of the case.
• Flex (FLEX), 5 October. Amy B. Schwetz is scheduled to join as finance chief of Flex's remaining segments. Her start date confirms that the leadership structure for those segments is in place.